2024 – Goldea Capital

The sales of VILVI GROUP September 2024

Written by Customer Service on October 10, 2024. Posted in Public Companies.

VILVI GROUP, which consists of Vilkyškių pieninė AB, “Modest” AB, Kelmės pieninė AB, “Kelmės pienas” UAB, “Pieno logistika” AB and “Baltic Dairy Board” SIA, consolidated sales for September 2024 amounted to 22.81 million EUR – 28.5% increase comparing to September 2023. The sales of the Group for period January – September 2024 amounted to 181.37 million EUR 17.9% increase comparing to the same period last year. Vilija Milaseviciute Economics and finance directorPhone: +370 441 55 102 Email: vilija.milaseviciute@vilvi.eu

Syensqo – Participation notification by BlackRock Finance Inc.

Written by Customer Service on October 10, 2024. Posted in Public Companies.

Participation notification by BlackRock Finance Inc. Brussels, Belgium – October 10, 2024 – 8:30 CESTAccording to Belgian transparency legislation (Law of May 2, 2007), BlackRock Finance Inc. (12 Throgmorton Avenue, London EC2N 2DL, UK) recently sent Syensqo the following transparency notifications indicating that it crossed the threshold of 3%. Here is the summary of the moves: Date on which the threshold was crossed Voting rights after the transaction Equivalent financial instruments after the transaction Total October 1, 2024 3.14% 0.65% 3.79% The latest notification, dated October 7, 2024, contains the following information: Reason for the notification: Acquisition or disposal of voting securities or voting rights As a result of the acquisition of Global Infrastructure Partners there has been a change...

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

Written by Customer Service on October 10, 2024. Posted in Earnings Releases And Operating Results.

PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS OF THE PERIOD Clinical development Masitinib platform: Ongoing re-examination by EMA and Health Canada of the marketing authorisation application for masitinib in amyotrophic lateral sclerosis (ALS) Update on the development of masitinib in progressive forms of multiple sclerosis following the ECTRIMS 2024 conference Positive results from the phase 2 study of masitinib in Covid-19 Strengthening the intellectual property of masitinib in mastocytosis Microtubule platform: Update on the AB8939 microtubule program and in in particular on the ability of AB8939 to generate a response on MECOM rearrangement Financial and corporate situation Operating deficit of 3.6 million euros as of June 30, 2024, down 59.5% compared to...

The net asset value of EfTEN Real Estate Fund AS shares as of 30.09.2024

Written by Customer Service on October 10, 2024. Posted in Public Companies.

EfTEN Real Estate Fund AS’s subsidiary, EfTEN Tähesaju tee OÜ, sold its property located at Tähesaju road 5, Tallinn in September. The property was sold for 4,675 thousand euros, which is 452 thousand euros below its book value. The sale generated 1.9 million euros in cash proceeds after loan repayments. The fund invested the proceeds from the sale into advance payments for logistics centers located at Härgmäe Str. 8 / Piimamehe Str. 7 and Paemurru road 3 in Tallinn. EfTEN Real Estate Fund AS generated consolidated rental income of 2,551 thousand euros in September, which is 26 thousand euros less compared to August. The decrease in rental income is primarily due to the sale of the Tähesaju property. The fund’s consolidated EBITDA for September was 2,191 thousand euros, an increase of 26 thousand euros from the previous month. For the...

Ascom has been awarded a major contract by the Canton of Zurich to install Ascom’s new Security Support System in nine penal institutions

Written by Customer Service on October 10, 2024. Posted in Public Companies.

Baar, Switzerland, 10 October 2024 Ascom is pleased to announce the expansion of its innovative App “Security Support System”, to nine penal institutions in Canton Zurich. The rollout of the first installation in Winterthur’s prison is scheduled for late 2024 and will continue through 2026 to eight additional correctional facilities in Canton Zurich. The entire project has a total value exceeding 3 million CHF. Ascom’s Security Support System has been exclusively designed to improve supervision and care in prisons and reintegration institutions to increase the safety and operational efficiency of employees working in prisons. It displays inmate profile for identification and location tracking data, and records further information for optimal care support. Currently, there is no comparable application in the market. The core of the solution...

Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY

Written by Customer Service on October 10, 2024. Posted in Public Companies.

The new VENTANA CLDN18 (43-14A) RxDx Assay helps fulfil an unmet medical need by enabling clinicians to identify patients with gastric or gastroesophageal junction (GEJ) cancer who may benefit from a targeted treatment option. CLDN18.2 is an emerging biomarker in gastric and GEJ cancers and helps predict the likelihood of response to targeted therapy. As the leader in companion diagnostics, Roche continues to build on its commitment to improve personalised healthcare to enable better patient outcomes. Basel, 10 October 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the VENTANAⓇ CLDN18 (43-14A) RxDx Assay is the first immunohistochemistry (IHC) companion diagnostic test to receive CE Mark approval for determining CLDN18 protein expression in tumours of patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma....

Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook

Written by Customer Service on October 10, 2024. Posted in Earnings Releases And Operating Results.

Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 October 2024 – 7:00 AM CET Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2024. Key Highlights Continued topline momentum with 12.1% reported revenue growth (15.7% at CER) and 12.2% organic growth at CER, delivering €214.5 million Strong organic growth across all regions and segments, underscoring the strength of our structural growth drivers Global operational excellence initiatives remain a key contributor to revenue development Three strategic acquisitions signed across all regions and segments: Purifarma (B&E, Brazil), Ritedose...

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year

Written by Customer Service on October 10, 2024. Posted in Public Companies.

Allschwil, Switzerland, October 10, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch, Basilea’s Chief Executive Officer, stated: “This is the fourth milestone payment for Asia Pacific and China this year and it reflects the significant medical need and strong growth momentum of Cresemba in this region. We are pleased to see that Cresemba continues to serve a medical need in patients suffering from life-threatening invasive mold infections.” The...

Pilgrim’s Pride Corporation to Host Third Quarter Earnings Call on October 31, 2024

Written by Customer Service on October 10, 2024. Posted in Public Companies.

GREELEY, Colo., Oct. 09, 2024 (GLOBE NEWSWIRE) — Pilgrim’s Pride Corporation (NASDAQ: PPC) announced today that it will release its third quarter 2024 financial results after the U.S. market closes on Wednesday, October 30. The company’s executives will review the results on a conference call and webcast on Thursday, October 31, 2024, at 7:00 a.m. MT (9:00 a.m. ET). Prepared remarks regarding the company’s financial and operational results will be followed by a question and answer period with Pilgrim’s executive management team. Investors and analysts may pre-register for the webcast to receive a unique PIN to gain immediate access to the call and bypass the live operator. Pre-registration may be completed at any time, including up to and after the call has begun, by accessing the company’s investor website at https://ir.pilgrims.com...

The Keg Royalties Income Fund announces October 2024 cash distribution

Written by Customer Service on October 10, 2024. Posted in Public Companies.

VANCOUVER, British Columbia, Oct. 09, 2024 (GLOBE NEWSWIRE) — The Keg Royalties Income Fund (the “Fund”) (TSX: KEG.UN) today announced that its October 2024 distribution of $0.0946 per unit has been declared and is payable to unitholders of record as at October 21, 2024. The October 2024 distribution will be paid on October 31, 2024. The Fund is a limited purpose, open-ended trust established under the laws of the Province of Ontario that, through The Keg Rights Limited Partnership, a subsidiary of the Fund, owns certain trademarks and other related intellectual property used by Keg Restaurants Ltd. (“KRL”). In exchange for use of those trademarks, KRL pays the Fund a royalty of 4% of gross sales of Keg restaurants included in the royalty pool. With approximately 10,000 employees, over 100 restaurants and annual system sales exceeding...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice